Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,742 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,284 of 1,487 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,032 total, page 19 of 41
Golf Instruction Versus Tai Chi for People With Parkinson's Disease
NCT03563807
Patient Receptiveness to Using Virtual Reality
NCT03528668
Effectiveness of Light for Enhancement of Cognition by Transcranial Repeated Application (ELECTRA)
NCT02817061
Comparison of 1,550-nm Laser and Fractional Radiofrequency Microneedle for the Treatment of Acne Scars in Ethnic Skin
NCT03380845
Effect of Combined Morphine and Duloxetine on Chronic Pain
NCT03249558
Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis
NCT03434028
Investigating the Feasibility and Implementation of Whole Genome Sequencing in Patients With Suspected Genetic Disorder
NCT03829176
How Body Awareness Promotes Mental Health During Yoga and Physical Exercise
NCT03553745
SMART Program for Paroxysmal Atrial Fibrillation
NCT03450993
Implementation and Evaluation of a Before School Physical Activity Program in Revere, MA
NCT03805295
Ipilimumab and Nivolumab in Leptomeningeal Metastases
NCT02939300
Healthy Hearts Healthy Minds
NCT03373110
Electronic Symptom Monitoring Intervention for Hospitalized Patients With Cancer
NCT03396510
A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk
NCT03416920
Solar Lighting to Reduce Indoor Air Pollution in Rural Uganda
NCT03351504
Inpatient Enrollment of Patient Portal App
NCT03431259
Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer
NCT03337399
Feasibility of an Individualized Goals of Care Discussion Guide for Advanced Breast Cancer
NCT03375827
Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy
NCT03290677
Psychological Intervention for Caregivers of Patients Undergoing Stem Cell Transplant
NCT03328663
Kidney Information Network for Disease Research and Education
NCT03321604
Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT
NCT03195777
Oxytocin and Cognitive Control in Adult ADHD
NCT03136263
Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer
NCT03360695
(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist
NCT03381261
Identification of Predictors for Coronary Plaque Erosion in Patients With Acute Coronary Syndrome
NCT03479723
tACS for Amyloid-β Reduction in Alzheimer's Disease
NCT03290326
Resilience Intervention for Older, HIV-Infected Women
NCT03071887
Cardiometabolic Disease and Pulmonary Hypertension
NCT03349775
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
NCT03256136
Study of a Transdiagnostic, Emotion-focused Group Intervention for Young Adults With Substance Use Disorders
NCT03315208
DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant
NCT03208127
Administration of Kisspeptin in Patients With Hyperprolactinemia
NCT02956447
Esophageal Deviation in Atrial Fibrillation Ablation
NCT03261973
Effect of a Probiotic Mixture on the Gut Microbiome and Fatigue in Patients With Quiescent Inflammatory Bowel Disease
NCT03266484
DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant
NCT03208244
A Text Messaging Program for Smokers in Primary Care
NCT03174158
Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study
NCT03176628
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
NCT03144804
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
NCT03292133
Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study
NCT03292146
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
NCT03279237
Pragmatic Collaborative Care for Cardiac Inpatients With Depression or Anxiety
NCT03118752
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
NCT03223779
Depression and Body Image Distress Following Mastectomy With Reconstruction
NCT03428399
A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT02985749
An Online Health Tool About Down Syndrome: Down Syndrome Clinic to You
NCT04227197
Integrating Mind-Body Skills With Physical Activity to Improve Physical and Emotional Outcomes in Patients With Chronic Pain
NCT03412916
Medication Education for Dosing Safety
NCT03223246
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
NCT03406208
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Massachusetts General Hospital: open-pipeline peers nationwide
Peers matched on 2,032 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Massachusetts General Hospital sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,032 trials (± recruiting share)
- National Institute of Allergy and Infectious Diseases (NIAID) · 2,006 trials · 8% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Rush University Medical Center · 17% recruiting · 320 trials
- OHSU Knight Cancer Institute · 17% recruiting · 211 trials
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
Related
What to do with this Massachusetts General Hospital page
2,032 registered trials is a research-attention snapshot, not an endorsement of Massachusetts General Hospital or any single study.
- 336 of Massachusetts General Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Massachusetts General Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Massachusetts General Hospital pipeline card: 2,032 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.